UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40793 OCEAN BIOMEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 87-1309280 55 Clav ...

公司经营风险 - 公司自成立以来已产生重大净亏损，预计未来仍将继续[21] - 公司需大量额外资金来维持运营，若无法筹集可能影响业务[21] - 公司是生物制药公司，运营历史有限，许多开发项目处于早期阶段[21] - 公司依赖第三方进行制造和供应，可能导致材料供应受限或中断[21] - 公司产品获批后可能无法获得市场认可，难以实现商业成功[21] 财务报告与投资风险 - 公司识别出财务报告内部控制存在重大缺陷，若整改无效可能影响财务报告准确性[22] - 公司普通股和认股权证价格可能波动，投资者可能损失全部或部分投资[22] 投资策略 - 公司将维持现金等价物投资组合，以降低未来风险[880] 贷款支付条款 - 根据第二街贷款修正案，公司执行时需支付0.3百万美元，首次额外交割收款后5个工作日内支付0.5百万美元等[882] - 根据麦克拉贷款修正案，公司执行时需支付0.2百万美元，首次额外交割收款后5个工作日内支付0.5百万美元等[882] 股票期权与薪酬费用 - 非员工董事获一次性授予75,000股非法定股票期权，行权价每股10美元，授予日公允价值每股3.73美元，2024和2023财年基于股票的薪酬费用分别为70万美元和60万美元[883][884][885] 金融工具估值参数 - 回售看跌期权负债和固定到期对价估值中，预期波动率147.5%，未来股价0.17 - 0.55美元，无风险利率4.17%[890] - 2024年可转换票据估值中，估计波动率55%，概率范围0% - 65%，无风险利率4.37%[892] - SPA认股权证估值中，估计波动率115%，概率范围0% - 65%，无风险利率4.29%[892] - 艾尔顿票据购买期权估值中，估计波动率13%，无风险利率4.4%，截至2024和2023年12月31日公允价值为零[893][894] 会计准则采用情况 - 公司于2023年1月1日提前采用ASU 2020 - 06，采用修改追溯法，对先前工具无影响[897] - 公司已采用ASU 2023 - 07，对2024年12月31日止年度合并财务报表及相关披露无重大影响[898] - ASU 2023 - 09将于2024年12月15日后开始的财年生效，公司正在评估其影响[899] 会计准则采用选择 - 公司选择利用新兴成长公司规定，按私人公司采用新标准的时间采用新或修订会计准则[900] 报告公司身份与披露豁免 - 公司为较小报告公司，若市场价值或年收入满足条件，可继续享受相关披露豁免[901]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Common stock, par value $0.0001 per share | OCEA | The NASDAQ Stock Market LLC | | Warrants, each exercisable for one share of common | | | | stock at an exercise price ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40793 OCEAN BIOMEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 87-1309280 55 Clave ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40793 OCEAN BIOMEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 87-1309280 55 Clav ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-40793 Ocean Biomedical, Inc. (Exact name of registrant as specified in its charter) Delaware 87-1309280 (State or other juri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-40793 OCEAN BIOMEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 87-1309280 55 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40793 OCEAN BIOMEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 87-1309280 55 Claverick St., Room 3 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-40793 Ocean Biomedical, Inc. (Exact name of registrant as specified in its charter) Delaware 87-1309280 (State or ot ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Ocean Biomedical, Inc. (Exact name of registrant as specified in its charter) | Delaware | 87-1309280 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organ ...